Korean Market
MATR
HLB bioStep
★

HLB bioStep Decides to Acquire 6 Billion Won of Its Own Convertible Bonds Before Maturity Due to Put Option Exercise, Eliminating 4.13% Potential Dilution

 
OWNR
HLB bioStep
★

HLB bioStep Non-Registered Executive Lee Hyeong-seok Increases Stake by 4,987 Shares in Open Market, Insider Ownership Now at 0.05%

 
MATR
HLB bioStep
★

HLB bioStep Decides Early Acquisition of 9.75 Billion Won in Convertible Bonds, Eliminating 6.54% Potential Dilution and Improving Capital Structure

 
OWNR
HLB bioStep
★

HLB bioStep CEO Seongjin Baek Increases Stake by 0.02%p via Open Market Purchase

 
EXCH
HLB bioStep
★

HLB bioStep Avoids Unfaithful Disclosure Designation for Facility Investment Reversal, Limited Impact on Share Price

 
OWNR
HLB bioStep
★

HLB bioStep Non-Registered Director Han Sang-ok Increases Stake to 0.04% via Open Market Purchase, Limited Impact on Shareholder Value

 
OWNR
HLB bioStep
★

HLB bioStep Inside Director Jin Yang-gon Reports Decrease in Shares Due to Stock Consolidation and Open Market Purchase, Ownership Percentage Slightly Increases

 
OWNR
HLB bioStep
★

HLB Increases Stake in HLB bioStep by 0.14% Reinforcing Control as Largest Shareholder

 
OWNR
HLB bioStep
★

HLB bioStep Non-Registered Executive Lee Hyeong-seok Acquires 3,000 Common Shares via Open Market Purchase, Increasing Stake to 0.02% - Minimal Impact on Stock Price

 
OWNR
HLB bioStep
★

HLB Increases Stake in HLB bioStep by 0.03% Through Open Market Purchase, Reinforcing Largest Shareholder Position

 
OWNR
HLB bioStep
★

HLB bioStep CEO Baek Seongjin Increases Stake to 0.06% via Open Market Purchase… Small but Positive Signal of Management Confidence

 
EXCH
HLB bioStep
★★

Notice of Unfaithful Disclosure Designation due to Revocation of New Facility Investment... Regulatory Risks and Potential Delisting Review

 
OWNR
HLB bioStep
★

HLB bioStep Non-Registered Director Myungjin Kim Reduces Stake from 0.34% to 0.10% via Open-Market Sales... Limited Impact on Share Price

 
EXCH
HLB bioStep
★

HLB BioStep Lifting of Trading Halt (Stock Split Listing Change)

 
PERI
HLB bioStep
★

HLB BioStep Q1 2026: Revenue Slightly Down, Net Loss Widens; Order Backlog of 24.6B Won